Penumbra, Inc. Common Stock (NY:PEN)

317.75 +0.19 (+0.06%)

Delayed Quote Updated: 2:33 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

9 Analysts Assess Penumbra: What You Need To Know ↗

October 07, 2025

Via Benzinga

3 Low-Volatility Stocks We Approach with Caution

October 06, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Topics Economy

A Look Into Penumbra Inc's Price Over Earnings ↗

October 03, 2025

Via Benzinga

$100 Invested In Penumbra 10 Years Ago Would Be Worth This Much Today ↗

October 03, 2025

Via Benzinga

Peering Into Penumbra Inc's Recent Short Interest ↗

October 02, 2025

Via Benzinga

Merit Medical Systems, ICU Medical, and Penumbra Stocks Trade Down, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics World Trade

What Does the Market Think About Penumbra? ↗

August 12, 2025

Via Benzinga

Expert Outlook: Penumbra Through The Eyes Of 7 Analysts ↗

July 30, 2025

Via Benzinga

Here's How Much $100 Invested In Penumbra 10 Years Ago Would Be Worth Today ↗

September 23, 2025

Via Benzinga

1 High-Flying Stock to Own for Decades and 2 We Turn Down

September 16, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Oscar Health, Penumbra, DexCom, Merit Medical Systems, and HCA Healthcare Shares Are Falling, What You Need To Know

September 10, 2025

A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.

Via StockStory

Topics Economy

3 Healthcare Stocks We’re Skeptical Of

September 08, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

3 Mid-Cap Stocks We Steer Clear Of

September 04, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 03, 2025

Via Benzinga

This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 03, 2025

Via Benzinga

Deep Dive Into Penumbra Stock: Analyst Perspectives (9 Ratings) ↗

September 02, 2025

Via Benzinga

This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

September 02, 2025

Via Benzinga

Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2

August 27, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - cardiology,...

Via StockStory

3 Cash-Heavy Stocks We Keep Off Our Radar

August 25, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance

August 12, 2025

Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue...

Via StockStory

1 Safe-and-Steady Stock with Promising Prospects and 2 We Question

August 11, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Penumbra PEN Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

3 Cash-Producing Stocks Walking a Fine Line

July 31, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Penumbra (PEN) Q2 Revenue Jumps 13% ↗

July 30, 2025

Via The Motley Fool

Penumbra (PEN) Shares Skyrocket, What You Need To Know

July 30, 2025

Shares of medical device company Penumbra (NYSE:PEN) jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and...

Via StockStory

Topics ETFs Stocks World Trade

Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday ↗

July 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 30, 2025

Via Benzinga

Penumbra’s (NYSE:PEN) Q2: Strong Sales, Stock Soars

July 29, 2025

Medical device company Penumbra (NYSE:PEN) announced better-than-expected revenue in Q2 CY2025, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue guidance of $1.36...

Via StockStory

Penumbra Inc (NYSE:PEN) Surpasses Q2 2025 Earnings and Revenue Estimates Amid Market Challenges ↗

July 29, 2025

Penumbra Inc (NYSE:PEN) beat Q2 2025 revenue and EPS estimates, reporting $339.46M and $0.86, driven by strong demand for its thrombectomy and vascular intervention tech.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.